Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Alzheimer's Disease, Psychosis, Agitation
Interventions
Lithium, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
Not listed
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
4
States / cities
Miami, Florida • Belmont, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced May 22, 2026, 5:15 AM EDT
Conditions
Dementia-related Psychosis
Interventions
Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
27
States / cities
Costa Mesa, California • Fullerton, California • Aventura, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced May 22, 2026, 5:15 AM EDT
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
KarXT, Placebo
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
55 Years to 90 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
58
States / cities
Homewood, Alabama • Phoenix, Arizona • Encino, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 22, 2026, 5:15 AM EDT
Conditions
Congestive Heart Failure, Diabetes, Coronary Artery Disease, Chronic Obstructive Pulmonary Disease, Cancer, Cerebrovascular Disease, Alzheimer's Disease, Psychotic Disorder, Major Depression
Interventions
Care Coordination
Behavioral
Lead sponsor
Mathematica Policy Research, Inc.
Other
Eligibility
Not listed
Enrollment
18,277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2016
U.S. locations
15
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Sunrise, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced May 22, 2026, 5:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers
Conditions
Parkinson Disease, Epilepsy, Alzheimer's Disease, Stroke, Autism, Depression, Schizophrenia
Interventions
Transcranial direct current stimulation, MRI
Device · Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 30 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced May 22, 2026, 5:15 AM EDT
Conditions
Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
Interventions
Brexpiprazole, OPC-34712, Placebo Oral Tablet
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
37
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Bellflower, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced May 22, 2026, 5:15 AM EDT
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
ML-007C-MA, Placebo
Drug
Lead sponsor
MapLight Therapeutics
Industry
Eligibility
55 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
27
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 22, 2026, 5:15 AM EDT
Conditions
Alzheimer's Disease, Psychosis, Agitation
Interventions
Haloperidol-Haloperidol, Haloperidol-Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
50 Years to 95 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced May 22, 2026, 5:15 AM EDT
Conditions
Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
Interventions
Brexpiprazole, OPC-34712
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
28
States / cities
Imperial, California • Lakewood, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced May 22, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available
Conditions
Alzheimer Disease
Interventions
Valproate, Placebo
Drug
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
55 Years to 90 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
46
States / cities
Sun City, Arizona • Tucson, Arizona • Irvine, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced May 22, 2026, 5:15 AM EDT
Conditions
Alzheimer Disease, Psychotic Disorders, Agitation, Aggression
Interventions
risperidone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
50 Years to 95 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
7
States / cities
Tuscaloosa, Alabama • Los Angeles, California • Norwalk, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced May 22, 2026, 5:15 AM EDT
Conditions
Alzheimer Disease
Interventions
aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 95 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
41
States / cities
Tuscaloosa, Alabama • Scottsdale, Arizona • Cerritos, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2013 · Synced May 22, 2026, 5:15 AM EDT
Completed Not applicable Interventional
Conditions
Alzheimer's Disease
Interventions
Olanzapine, Quetiapine, Risperidone, Citalopram
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
34
States / cities
Tuscaloosa, Alabama • Irvine, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2015 · Synced May 22, 2026, 5:15 AM EDT
Conditions
Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
Interventions
bifeprunox, Placebo
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
65 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
35
States / cities
Phoenix, Arizona • Carson, California • Long Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2015 · Synced May 22, 2026, 5:15 AM EDT
Conditions
Alzheimer Disease
Interventions
Trazodone, Haloperidol
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced May 22, 2026, 5:15 AM EDT
Conditions
Alzheimer Disease
Interventions
active tDCS
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
60 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced May 22, 2026, 5:15 AM EDT
Conditions
Alzheimer's Disease Psychosis
Interventions
ACP-204
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
55 Years to 95 Years
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
19
States / cities
Costa Mesa, California • Fresno, California • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 22, 2026, 5:15 AM EDT
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
KarXT
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
55 Years to 90 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
146
States / cities
Homewood, Alabama • Chandler, Arizona • Gilbert, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 22, 2026, 5:15 AM EDT
Conditions
Alzheimer Disease
Interventions
aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 95 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
6
States / cities
Rosemead, California • Miami, Florida • Nashville, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2013 · Synced May 22, 2026, 5:15 AM EDT
Conditions
Alzheimer's Disease Psychosis
Interventions
ACP-204, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
55 Years to 95 Years
Enrollment
1,074 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
45
States / cities
Chandler, Arizona • Scottsdale, Arizona • Anaheim, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced May 22, 2026, 5:15 AM EDT
Conditions
Alzheimer Disease, Dementia Alzheimers, Dementia, Cognitive Impairment, Mild Cognitive Impairment, Neurodegenerative Diseases, Neurocognitive Disorders, Neurocognitive Dysfunction, Cognitive Dysfunction, Mental Disorder
Interventions
Emerald Device Monitoring
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced May 22, 2026, 5:15 AM EDT
Conditions
Senile Dementia, Alzheimer Type, Dementia, Alzheimer Type, Alzheimer Disease, Dementia
Interventions
risperidone, quetiapine, olanzapine, divalproex
Drug
Lead sponsor
Emory University
Other
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2013 · Synced May 22, 2026, 5:15 AM EDT
Conditions
Alzheimer Disease, Psychosis
Interventions
KarXT, KarX-EC, KarXT + KarX-EC Arm Matching Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
55 Years to 90 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Gilbert, Arizona • Chino, California • Naples, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 22, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers
Conditions
Schizophrenia, Alzheimer's Disease, Dementia
Interventions
Aripiprazole, Olanzapine, Risperidone
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
40 Years and older
Enrollment
406 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2018 · Synced May 22, 2026, 5:15 AM EDT